U.S. Capital Wealth Advisors LLC Decreases Stake in AbbVie Inc. $ABBV

U.S. Capital Wealth Advisors LLC trimmed its stake in shares of AbbVie Inc. (NYSE:ABBV) by 30.9% in the third quarter, Holdings Channel.com reports. The fund owned 47,638 shares of the company’s stock after selling 21,256 shares during the period. U.S. Capital Wealth Advisors LLC’s holdings in AbbVie were worth $11,030,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Marshall & Sullivan Inc. WA purchased a new stake in AbbVie during the second quarter worth $25,000. Evolution Wealth Management Inc. acquired a new stake in AbbVie in the 2nd quarter valued at about $26,000. TD Capital Management LLC increased its holdings in AbbVie by 82.9% during the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after acquiring an additional 58 shares in the last quarter. Spurstone Advisory Services LLC acquired a new position in AbbVie during the second quarter worth about $28,000. Finally, Financial Gravity Companies Inc. acquired a new position in shares of AbbVie in the second quarter worth $36,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Erste Group Bank cut shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. JPMorgan Chase & Co. lifted their price objective on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Berenberg Bank raised shares of AbbVie from a “hold” rating to a “buy” rating and upped their price target for the stock from $170.00 to $270.00 in a research report on Wednesday, September 17th. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $289.00 price target (up previously from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $245.84.

AbbVie Price Performance

NYSE ABBV opened at $227.44 on Friday. The company’s 50 day simple moving average is $226.63 and its 200 day simple moving average is $210.98. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The firm has a market capitalization of $401.98 billion, a PE ratio of 172.30, a P/E/G ratio of 1.27 and a beta of 0.36. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period last year, the firm posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio is presently 496.97%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.